193 related articles for article (PubMed ID: 38228495)
21. LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma.
Kawasaki K; Kuboki S; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
Liver Int; 2021 Apr; 41(4):865-881. PubMed ID: 33249719
[TBL] [Abstract][Full Text] [Related]
22. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
Chen J; Tang Y; Qin D; Yu X; Tong H; Tang C; Tang Z
J Transl Med; 2023 Dec; 21(1):923. PubMed ID: 38124204
[TBL] [Abstract][Full Text] [Related]
23. Matricellular proteins in intrahepatic cholangiocarcinoma.
Sirica AE
Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
[TBL] [Abstract][Full Text] [Related]
24. The role of Tripartite motif containing 59 (TRIM59) in the proliferation and prognosis of intrahepatic cholangiocarcinoma.
Zhang JN; Ding DY; Yang SY; Tao QF; Yang Y; Zhou WP
Pathol Res Pract; 2022 Aug; 236():153989. PubMed ID: 35753134
[TBL] [Abstract][Full Text] [Related]
25. IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
Li H; Lan T; Liu H; Liu C; Dai J; Xu L; Cai Y; Hou G; Xie K; Liao M; Li J; Huang J; Yuan K; Wang G; Zeng Y; Wu H
Hepatology; 2022 Jun; 75(6):1402-1419. PubMed ID: 34758510
[TBL] [Abstract][Full Text] [Related]
26. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
[TBL] [Abstract][Full Text] [Related]
27. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
Yang H; Yan M; Li W; Xu L
J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
[TBL] [Abstract][Full Text] [Related]
28. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
29. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
30. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance.
Chen J; Gao Z; Li X; Shi Y; Tang Z; Liu W; Zhang X; Huang A; Luo X; Gao Q; Ding G; Song K; Zhou J; Fan J; Fu X; Ding Z
Cancer Med; 2023 Jan; 12(1):459-471. PubMed ID: 35676831
[TBL] [Abstract][Full Text] [Related]
31. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
33. PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma.
Li H; Wu Z; Zhong R; Zhang Q; Chen Q; Shen Y
Med Oncol; 2022 Oct; 39(12):250. PubMed ID: 36209344
[TBL] [Abstract][Full Text] [Related]
34. YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
Huang X; Zhu L; Wang L; Huang W; Tan L; Liu H; Huo J; Su T; Zhang M; Kuang M; Li X; Dai Z; Xu L
J Gastroenterol Hepatol; 2022 Jun; 37(6):1156-1168. PubMed ID: 35233828
[TBL] [Abstract][Full Text] [Related]
35. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway.
Shen J; Zhou Y; Zhang X; Peng W; Peng C; Zhou Q; Li C; Wen T; Shi Y
Aging (Albany NY); 2019 Nov; 11(21):9280-9294. PubMed ID: 31689237
[TBL] [Abstract][Full Text] [Related]
36. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome.
Yang XW; Li L; Hou GJ; Yan XZ; Xu QG; Chen L; Zhang BH; Shen F
Oncotarget; 2017 Jan; 8(5):7710-7721. PubMed ID: 28032598
[TBL] [Abstract][Full Text] [Related]
37. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
38. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256.
Chen S; Chen Z; Li Z; Li S; Wen Z; Cao L; Chen Y; Xue P; Li H; Zhang D
Cell Death Dis; 2022 Jan; 13(1):94. PubMed ID: 35091535
[TBL] [Abstract][Full Text] [Related]
40. COTE1 Facilitates Intrahepatic Cholangiocarcinoma Progression via Beclin1-Dependent Autophagy Inhibition.
Zhang H; Chen S; Xu S; Li X
Biomed Res Int; 2023; 2023():5491682. PubMed ID: 37780485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
